Form 4 for BIIB Biogen
Accepted 2023-03-06 00:00:00 ET · period of report 2023-03-02 · accession 0001127602-23-009142 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-03-06 | 2023-03-02 | BIIB | Singhal Priya | Head of Development | F - Tax | $268.75 | -687 | 3,410 | -17% | -$184.6K |
| D | 2023-03-06 | 2023-03-02 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +297 | 3,554 | +9% | $0 |
| D | 2023-03-06 | 2023-03-02 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | -297 | 341 | -47% | $0 |
| D | 2023-03-06 | 2023-03-02 | BIIB | Singhal Priya | Head of Development | J - Other | $0.00 | -341 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-02 | F | D | 543 | $268.75 | 3,257.39 | D | — | — | |
| 2 | Common | Common Stock | 2023-03-02 | F | D | 144 | $268.75 | 3,410.39 | D | — | — | |
| 3 | Common | Common Stock | 2023-03-02 | M | A | 297 | $0.00 | 3,554.39 | D | — | — | |
| 4 | Derivative | Restricted Stock Unit | 2023-03-02 | M | D | 297 | $0.00 | 341 | D | $0.00 · — to 2023-03-02 | 297 Common Stock | (F2) This award was granted to the reporting person on March 2, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |
| 5 | Derivative | Restricted Stock Unit | 2023-03-02 | J | D | 341 | $0.00 | 0 | D | $0.00 · — to 2023-03-02 | 341 Common Stock | (F3) This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. (F2) This award was granted to the reporting person on March 2, 2020. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). |